D2.528 - Corticophobia Among Caregivers of Children with Atopic Diseases: Causes and Outcomes

Corticosteroids are cornerstone therapies for atopic dermatitis, asthma, and allergic rhinitis. However, parental concerns about corticosteroid use (corticophobia) may impair adherence and disease control. This study aimed to determine the prevalence, causes, and effects of corticophobia among caregivers of children with allergic diseases.

This cross-sectional study was conducted among caregivers of children followed at a Pediatric Allergy and Immunology Clinic. A structured questionnaire assessed sociodemographic data, corticosteroid use, perceived and experienced side effects, sources of concern, and the impact on treatment adherence.

A total of 225 caregivers participated. The children had a median age of 8 years (IQR 5.4–12), and 57.8% were male. The most common diagnoses were asthma (62.2%) and atopic dermatitis (14.7%). Corticosteroid use included inhaled (80.4%), topical (18.7%), intranasal (18.7%), oral (17.3%), and intravenous (8%) forms. Twelve children (5.3%) experienced adverse effects, most often weight gain (n=6) and skin thinning (n=4). Higher educational level was associated with greater awareness of corticosteroid-related side effects and increased anxiety regarding growth retardation, hyperglycemia, and edema. Overall, 48.4% reported occasional concern and 40.4% worried about all formulations. The main source of concern was relatives or friends (25.3%). Despite this, 64.8% had never received professional counseling. Corticophobia led to shortening or dose reduction of treatment in 18.6% of cases.

Corticophobia is common among caregivers of children with allergic diseases, often driven by non-medical information sources. Targeted, physician-led education is essential to reduce fear and improve adherence to corticosteroid therapy.